Dynavax to Present at Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference

Share Article

Dynavax Technologies Corporation (Nasdaq:DVAX) announced today Michael S. Ostrach, Vice President and Chief Business Officer, will present an overview of the company at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference on Wednesday, March 5, 2008 at 1:00 p.m. ET (10:00 a.m. PT) in New York City. The presentation will be webcast.

News Image

    To access the live audio broadcast and the subsequent archived audio recordings of the company presentation, please log onto the company's website at http://www.dynavax.com under the "Investors'" section.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV(TM), a hepatitis B vaccine in Phase 3 partnered with Merck & Co., Inc.; TOLAMBA(TM), a ragweed allergy immunotherapy in Phase 2; a therapy for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The NIH partially funds our preclinical work on a vaccine for influenza. SDI funds our colorectal cancer and hepatitis C therapeutic programs, and Deerfield Management has committed funding for our allergy programs. While Deerfield, NIH and SDI provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization. For more information, please visit http://www.dynavax.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website